NCT03189511 (FluvaBAT) is a Phase 4 clinical trial of Fluvastatin in Adipose Tissue, Brown, sponsored by University of Zurich.

Who is sponsoring NCT03189511?

NCT03189511 is sponsored by University of Zurich.

What drugs are being tested in NCT03189511?

Interventions in NCT03189511: Fluvastatin.

What condition does NCT03189511 study?

NCT03189511 studies Adipose Tissue, Brown, Insulin Resistance, Clinical Trial.

Is NCT03189511 still recruiting?

NCT03189511 is currently completed. Last updated 31 May 2018.

Last reviewed 2018-05-31 · How we verify

NCT03189511: FluvaBAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Fluvastatin on Brown Fat Activity

Completed Phase 4 Last updated 31 May 2018

What this trial tests

Phase 4 trial testing Fluvastatin in Adipose Tissue, Brown in 17 participants. Completed in 19 February 2018.

Timeline

31 May 2017

Primary endpoint
23 January 2018

19 February 2018

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	basic science
Enrollment	17
Start date	31 May 2017
Primary completion	23 January 2018
Estimated completion	19 February 2018
Sites	2 locations across Switzerland

Drugs / interventions tested

Fluvastatin (FLUVASTATIN) — full drug profile →

Conditions studied

Adipose Tissue, Brown — all drugs for Adipose Tissue, Brown →
Insulin Resistance — all drugs for Insulin Resistance →
Clinical Trial — all drugs for Clinical Trial →

Sponsor

University of Zurich

Who can join

Adults 18 to 40, male only, with Adipose Tissue, Brown or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to elucidate the effects of Fluvastatin on brown adipose tissue activity in humans.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecules for fat combustion: targeting obesity.
Liu J, Wang Y, Lin L. · · 2019 · cited 91× · PMID 30976490 · DOI 10.1016/j.apsb.2018.09.007
The evolving view of thermogenic fat and its implications in cancer and metabolic diseases.
Yin X, Chen Y, Ruze R, Xu R, et al · · 2022 · cited 43× · PMID 36114195 · DOI 10.1038/s41392-022-01178-6
Outdoor Temperature Influences Cold Induced Thermogenesis in Humans.
Senn JR, Maushart CI, Gashi G, Michel R, et al · · 2018 · cited 25× · PMID 30190681 · DOI 10.3389/fphys.2018.01184
Relation of diet-induced thermogenesis to brown adipose tissue activity in healthy men.
Loeliger RC, Maushart CI, Gashi G, Senn JR, et al · · 2021 · cited 19× · PMID 33225717 · DOI 10.1152/ajpendo.00237.2020
Comparison of [<sup>18</sup>F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity.
Fischer JGW, Maushart CI, Becker AS, Müller J, et al · · 2020 · cited 10× · PMID 32699996 · DOI 10.1186/s13550-020-00665-7
Low-dose <sup>18</sup>F-FDG TOF-PET/MR for accurate quantification of brown adipose tissue in healthy volunteers.
Ter Voert EEGW, Svirydenka H, Müller J, Becker AS, et al · · 2020 · cited 8× · PMID 31974702 · DOI 10.1186/s13550-020-0592-8
Free Thyroxine Levels are Associated with Cold Induced Thermogenesis in Healthy Euthyroid Individuals.
Maushart CI, Senn JR, Loeliger RC, Kraenzlin ME, et al · · 2021 · cited 7× · PMID 34194392 · DOI 10.3389/fendo.2021.666595
Fluvastatin Reduces Glucose Tolerance in Healthy Young Individuals Independently of Cold Induced BAT Activity.
Felder M, Maushart CI, Gashi G, Senn JR, et al · · 2021 · cited 2× · PMID 34858338 · DOI 10.3389/fendo.2021.765807

Verify or expand the search:

Other trials of Fluvastatin

Trials testing the same drug.

NCT04285749 — Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas · EARLY_PHASE1 · withdrawn
NCT03510715 — An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia · Phase 3 · completed
NCT03510884 — An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia · Phase 3 · completed

Other recruiting trials for Adipose Tissue, Brown

Currently open trials in the same condition.

NCT04352244 — The Physiology of Human Brown Adipose Tissue · recruiting
NCT03541096 — Winter-Swimming and Brown Adipose Tissue Activity in Middel-aged Obese Subjects (WinterBAT). · NA · active not recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03189511 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 31 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03189511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing